SCI-PUB

Non-Hodgkin's Lymphomas

Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy.

While the use of chimeric antigen receptor-T (CAR-T) therapy for T-cell malignancies is in the early stage of clinical trials, it exhibits substantial potential to offer long-term remission for patients with refractory/relapsed (R/R) T-cell malignancies...

DOI: 10.1002/ajh.27094

Zhang X, Yang J, Li J, Qiu L, Zhang J, Lu Y, Zhao YL, Jin D, Li J, Lu P

American journal of hematology, 2023-09-24

Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.

Mantle cell lymphoma (MCL) is a rare non-Hodgkin lymphoma that frequently becomes chemoresistant over time...

DOI: 10.1080/10428194.2023.2259528

Ip A, Petrillo A, Della Pia A, Lee GG, Gill S, Varughese T, Zenreich J, Gutierrez M, Zhang J, Ahn J, Bharani V, Nejad AS, Pascual L, Feldman TA, Leslie LA, Goy AH

Leukemia & lymphoma, 2023-09-24

Tafasitamab and lenalidomide in large B cell lymphoma: real-world outcomes in a multicenter retrospective study.

In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed/refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared to the L-MIND registration clinical trial for TL..

DOI: 10.1182/blood.2023021274

Qualls DA, Lambert N, Caimi PF, Merrill MH, Pullarkat P, Godby RC, Bond DA, Wehmeyer GT, Romancik JT, Amoozgar B, Leslie LA, Nastoupil LJ, Crombie JL, Abramson JS, Khurana A, Nowakowski GS, Maddocks KJ, Rutherford SC, Kahl BS, Okwali M, Buege MJ, Ses

Blood, 2023-09-23

Single-agent rituximab is an effective salvage therapy in pretreated hairy cell leukemia patients.

Single-agent rituximab can be a suitable treatment in hairy cell leukemia (HCL) patients relapsing after repeated courses of purine analogs, if purine analogs are contraindicated (e.g...

DOI: 10.1182/bloodadvances.2023010742

Broccoli A, Argnani L, Nanni L, Stefoni V, Pellegrini C, Casadei B, Gugliotta G, Carella M, Coppola PE, Bagnato G, Zinzani PL

Blood advances, 2023-09-23

Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin's lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group.

PET-2-positive residuals of AS-HL are mostly located in the mediastinum, and a majority of patients have few affected regions. The risk of progression was twofold higher in patients with more than two positive regions in PET-2.

DOI: 10.1007/s00259-023-06431-w

Ferdinandus J, van Heek L, Roth K, Dietlein M, Eich HT, Baues C, Borchmann P, Kobe C

European journal of nuclear medicine and molecular imaging, 2023-09-23

Validation of the ΔSUV for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial.

We recommend the use of the ΔSUVmax alone rather than the Menton 2011 criteria for assessing the interim metabolic response in patients with diffuse large B-cell lymphoma, except when the baseline SUVmax is less than 10.0.

DOI: 10.2967/jnumed.123.265871

Itti E, Blanc-Durand P, Berriolo-Riedinger A, Kanoun S, Kraeber-Bodéré F, Meignan M, Gat E, Le Gouill S, Casasnovas RO, Bodet-Milin C

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023-09-23

Lugtenburg PJ, Mutsaers PGNJ. How I treat older patients with DLBCL in the frontline setting. Blood. 2023;141(21):2566-2575.

No abstract text is available for this article

DOI: 10.1182/blood.2023021551

Blood, 2023-09-22

COVID-19 in patients with classic and variant hairy cell leukemia.

Hairy cell leukemia (HCL), like its variant HCLv, is a B-cell malignancy associated with decreased humoral immunity...

DOI: 10.1182/bloodadvances.2023011147

Kreitman RJ, Yu T, James L, Feurtado JC, Eager H, Sierra Ortiz O, Gould M, Mauter J, Zhou H, Burbelo PD, Cohen JI, Wang HW, Yuan CM, Arons E

Blood advances, 2023-09-22

Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment.

T cell lymphoma (TCL) is a highly heterogeneous group of diseases with a poor prognosis and low 5-year overall survival rate...

DOI: 10.1016/j.omto.2023.07.007

Xia B, Lin K, Wang X, Chen F, Zhou M, Li Y, Lin Y, Qiao Y, Li R, Zhang W, He X, Zou F, Li L, Lu L, Chen C, Li W, Zhang H, Liu B

Molecular therapy oncolytics, 2023-09-22

Real-world experience of CAR T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma.

The emergence of chimeric antigen receptor (CAR) T-cell therapy has changed the treatment landscape for diffuse large B-cell lymphoma (DLBCL); however, real-world experience reporting outcomes among older patients treated with CAR T-cell therapy is limited...

DOI: 10.1182/blood.2023020197

Chihara D, Liao L, Tkacz J, Franco A, Lewing B, Kilgore KM, Nastoupil LJ, Chen L